Loading clinical trials...
Loading clinical trials...
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients (The INCLUDE Trial)
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Intermountain Healthcare Hospitals and Clinics
Salt Lake City, Utah, United States
Start Date
January 30, 2025
Primary Completion Date
January 1, 2028
Completion Date
September 1, 2028
Last Updated
May 6, 2025
400
ESTIMATED participants
Clinical Pharmacy Team
OTHER
Usual Care
OTHER
Lead Sponsor
Intermountain Health Care, Inc.
NCT06813911
NCT06295679
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06541691